This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Childers WE , Elokely KM , Abou-Gharbia M
The Resurrection of Phenotypic Drug Discovery
ACS Med Chem Lett. 2020 Oct 8;11(10) :1820-1828
PMID: 33062159 PMCID: PMC7549108
AbstractPrior to genetic mapping, the majority of drug discovery efforts involved phenotypic screening, wherein compounds were screened in either in vitro or in vivo models thought to mimic the disease state of interest. While never completely abandoning phenotypic approaches, the labor intensive nature of such tests encouraged the pharmaceutical industry to move away from them in favor of target-based drug discovery, which facilitated throughput and allowed for the efficient screening of large numbers of compounds. However, a consequence of reliance on target-based screening was an increased number of failures in clinical trials due to poor correlation between novel mechanistic targets and the actual disease state. As a result, the field has seen a recent resurrection in phenotypic drug discovery approaches. In this work, we highlight some recent phenotypic projects from our industrial past and in our current academic drug discovery environment that have provided encouraging results.
Notes1948-5875 Childers, Wayne E Elokely, Khaled M Abou-Gharbia, Magid Journal Article ACS Med Chem Lett. 2020 Mar 6;11(10):1820-1828. doi: 10.1021/acsmedchemlett.0c00006. eCollection 2020 Oct 8.